Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited Fundamental Analysis
Shandong Weigao Group Medical Polymer Company Limited (SHWGY) shows moderate financial fundamentals with a PE ratio of 10.24, profit margin of 15.02%, and ROE of 8.22%. The company generates $13.0B in annual revenue with weak year-over-year growth of -1.08%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 48.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SHWGY's fundamental strength across five key dimensions:
Efficiency Score
WeakSHWGY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSHWGY trades at attractive valuation levels.
Growth Score
WeakSHWGY faces weak or negative growth trends.
Financial Health Score
ExcellentSHWGY maintains a strong and stable balance sheet.
Profitability Score
ModerateSHWGY maintains healthy but balanced margins.
Key Financial Metrics
Is SHWGY Expensive or Cheap?
P/E Ratio
SHWGY trades at 10.24 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SHWGY's PEG of -0.33 indicates potential undervaluation.
Price to Book
The market values Shandong Weigao Group Medical Polymer Company Limited at 0.84 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.49 times EBITDA. This is generally considered low.
How Well Does SHWGY Make Money?
Net Profit Margin
For every $100 in sales, Shandong Weigao Group Medical Polymer Company Limited keeps $15.02 as profit after all expenses.
Operating Margin
Core operations generate 15.58 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.22 in profit for every $100 of shareholder equity.
ROA
Shandong Weigao Group Medical Polymer Company Limited generates $5.44 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shandong Weigao Group Medical Polymer Company Limited produces operating cash flow of $2.64B, showing steady but balanced cash generation.
Free Cash Flow
Shandong Weigao Group Medical Polymer Company Limited generates strong free cash flow of $2.04B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.79 in free cash annually.
FCF Yield
SHWGY converts 10.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
10.24
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.33
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.84
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.53
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How SHWGY Stacks Against Its Sector Peers
| Metric | SHWGY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 10.24 | 28.25 | Better (Cheaper) |
| ROE | 8.22% | 780.00% | Weak |
| Net Margin | 15.02% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.23 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 3.73 | 4.66 | Strong Liquidity |
| ROA | 5.44% | -14687.00% (disorted) | Weak |
SHWGY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shandong Weigao Group Medical Polymer Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
24.54%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
10.48%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
18.56%
Industry Style: Defensive, Growth, Innovation
High Growth